{
  "docId": "019de072-f0cb-7745-907c-f9e6b87d2817",
  "docSlug": "e5afd111c5ca3d26ccce5d5b91b81d60",
  "documentTitle": "BioNTech | Investor Day Presentation Deck | 156 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 67,
  "pageCount": 120,
  "prevPage": 66,
  "nextPage": 68,
  "slideType": "comparison_table",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 24,
  "notes": "The table highlights that all tested Omicron-modified vaccines met the superiority criterion (lower bound of 95% CI for GMR > 1.0).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-f0cb-7745-907c-f9e6b87d2817/67",
  "deckHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817",
  "deckJsonHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817.json",
  "deckAnchorHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817#slide-67",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "callout",
      "text": "GMR superiority criterion: the lower bound of 95% confidence interval for GMR is >1.0",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73a2cd27-9653-4c4a-93b5-b85c0d0fb75c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "Participants WITHOUT evidence of infection up to 1 month after the study vaccination",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d638c533-7cb6-4f46-ad8e-4b19b46194a0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Multiple hypotheses are to be evaluated in sequential order for alpha control. Declaration of OMI 30 µg simple superiority pending outcome of additional hypotheses. Note: Omicron BA.1 NT50 measured using validated 384-well assay. Internal data.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "149eb77e-a6ff-4fe9-b2fd-51154c674da3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "table",
      "text": "Assay, Vaccine groups, n, GMT (95% CI) 1M post-dose, GMR (95% CI), Met superiority (Y/N)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8264751c-1135-4fba-8d28-9a515ef78b08",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Variant-adapted vaccines | Omicron BA.1 GMR consistent with simple superiority criterion for Omicron-modified vaccines (>55y participants)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "433ebbc0-268c-428c-a07d-d1b0915f90d7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 70,
      "from": 60,
      "beatId": "ad024950-7f4b-4056-b7c8-680591fc503c",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Opportunity",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The presentation highlights the market opportunity in infectious diseases and oncology",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}